The Acarbose Cardiovascular Evaluation (ACE) trial was launched on Friday 11th April 2008 at the 10th South China International Congress of Cardiology in Guangzhou, China. ACE is a multi-centre clinical outcome trial coordinated by the Diabetes Trial Unit and run in China with the guidance of an international Steering Committee of diabetologists and cardiologists.
The primary objective of ACE is to determine whether reducing post prandial glucose excursions, using the alphaglucosidase inhibitor acarbose, can reduce cardiovascular-related morbidity and mortality in patients who have established cardiovascular disease and "prediabetes" (IGT).
7,500 eligible patients will be randomised by 150 clinical centres in mainland China and Hong Kong to double-blind therapy with acarbose or placebo, in addition to optimised therapy for cardiovascular disease, and followed for a minimum of 4 years.
The ACE trial is expected to report its results in 2014.